Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with type 2 diabetes.

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

A study shed light on the side effects of mental health, narrowing down those who are genetically more vulnerable.

Start listening today! The findings showed that dopamine signals in the two parts of the brain rise and fall in complex ...

Dopamine is the brain's motivational spark, driving us to chase what feels good, say scrolling another reel on social media, and steer clear of what doesn't, like touching a hot stove. But scientists ...

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly ...

A new study raises mental health concerns about popular weight loss drugs like Ozempic and Mounjaro. These GLP-1 agonists, while effective for appetite control, may disrupt dopamine pathways linked to ...

Dopamine is the brain's motivational spark, driving us to chase what feels good, say scrolling another reel on social media, ...

Vision loss, thyroid tumours, kidney problems, gallbladder issues and pancreatitis are some of the concerning side effects ...

Parkinson’s Disease is a neurodegenerative disorder that affected predominately the Dopamine-producing neurons in a specific ...

Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...